InhaleRx Limited (AU:IRX) has released an update.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
InhaleRx Limited has secured a $38.5 million funding agreement with Clendon Biotech Capital to advance its clinical development projects, IRX-211 and IRX-616a, through Phase 2 trials. This strategic partnership enables the company to focus on creating breakthrough inhaled therapies for pain management and mental health, potentially reaching Phase 3 within the next few years. InhaleRx aims to solidify its position as a leader in inhaled therapeutics, addressing unmet medical needs and enhancing patient care.
For further insights into AU:IRX stock, check out TipRanks’ Stock Analysis page.